The 2026 landscape for Hypertrophic Cardiomyopathy (HCM) treatment has reached a historic turning point as the industry shifts from merely slowing the heart rate to directly fixing the muscle's hypercontractility. For over 50 years, patients relied on repurposed beta-blockers and calcium channel blockers that often left them fatigued and limited in their daily lives. However, 2026 marks the...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
คลิกดาวน์โหลด
thai
English
French
Spanish
Portuguese
Italiano
Portuguese (Brazil)
china